gefitinib has been researched along with methotrexate in 31 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (methotrexate) | Trials (methotrexate) | Recent Studies (post-2010) (methotrexate) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 41,593 | 5,666 | 11,969 |
| Protein | Taxonomy | gefitinib (IC50) | methotrexate (IC50) |
|---|---|---|---|
| Thymidylate synthase | Escherichia coli | 1.8 | |
| nuclear receptor coactivator 3 isoform a | Homo sapiens (human) | 0.211 | |
| Toll-like receptor 4 | Homo sapiens (human) | 1.04 | |
| Fatty-acid amide hydrolase 1 | Mus musculus (house mouse) | 0.08 | |
| Dihydrofolate reductase | Homo sapiens (human) | 0.0522 | |
| Dihydrofolate reductase | Mus musculus (house mouse) | 0.0331 | |
| Dihydrofolate reductase | Bos taurus (cattle) | 0.0348 | |
| Dihydrofolate reductase | Gallus gallus (chicken) | 0.0545 | |
| Dihydrofolate reductase | Enterococcus faecium | 0.0014 | |
| Dihydrofolate reductase | Lacticaseibacillus casei | 0.0138 | |
| Thymidylate synthase | Homo sapiens (human) | 0.343 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0147 | |
| Thymidylate synthase | Escherichia coli K-12 | 0.0181 | |
| Dihydrofolate reductase | Escherichia coli K-12 | 0.1529 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Plasmodium falciparum K1 | 0.084 | |
| Folate receptor beta | Homo sapiens (human) | 0.1585 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0011 | |
| Cytochrome P450 11B1, mitochondrial | Bos taurus (cattle) | 0.0012 | |
| Folate receptor alpha | Homo sapiens (human) | 0.2263 | |
| Dihydrofolate reductase | Pneumocystis carinii | 0.0717 | |
| Histidine decarboxylase | Rattus norvegicus (Norway rat) | 0.0014 | |
| Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.01 | |
| Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.01 | |
| Delta-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Mu-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Kappa-type opioid receptor | Rattus norvegicus (Norway rat) | 0.003 | |
| Reduced folate transporter | Homo sapiens (human) | 0.012 | |
| Dihydrofolate reductase | Mycobacterium tuberculosis H37Rv | 0.0174 | |
| Folylpolyglutamate synthase, mitochondrial | Homo sapiens (human) | 3.2 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 0.0547 | |
| Bifunctional dihydrofolate reductase-thymidylate synthase | Trypanosoma cruzi | 0.11 | |
| Dihydrofolate reductase | Bacillus anthracis | 0.0136 | |
| Dihydrofolate reductase | Rattus norvegicus (Norway rat) | 0.0047 | |
| Proton-coupled folate transporter | Homo sapiens (human) | 0.1207 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (25.81) | 29.6817 |
| 2010's | 19 (61.29) | 24.3611 |
| 2020's | 4 (12.90) | 2.80 |
| Authors | Studies |
|---|---|
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| El-Subbagh, HI; Ghaly, MA; Maarouf, AR; Sabry, MA | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK; Symonds, RP | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE | 1 |
| Teng, KY; Xu, RH | 1 |
| Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z | 1 |
| Kim, JJ | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Autry, AM | 1 |
| Dimitriadis, E; Gao, Y; Greenall, SA; Horne, AW; Johns, TG; Kaitu'u-Lino, T; Menkhorst, E; Nilsson, UW; Saglam, B; Tong, S; Whitehead, C; Wilmann, T | 1 |
| Critchley, HOD; Duncan, WC; Horne, AW; Johns, TG; Nilsson, UW; Skubisz, MM; Tong, S; Wallace, EM | 1 |
| Duncan, WC; Horne, AW; Johns, TG; Neil, P; Skubisz, MM; Tong, S; Wallace, EM | 1 |
| Horne, AW; Skubisz, MM; Tong, S | 1 |
| Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP | 1 |
| Brownfoot, F; Campbell, L; Ellett, L; Hannan, NJ; Hastie, R; Horne, AW; Kaitu'u-Lino, TJ; Lim, E; Sluka, P; Tong, S | 1 |
| Bhattacharya, S; Colin Duncan, W; Doust, A; Horne, AW; Johns, TG; Krzys, N; Mollison, J; Neil, P; Robinson, M; Skubisz, MM; Tong, S; Wallace, E | 1 |
| Bhattacharya, S; Bottomley, C; Bourne, T; Coomarasamy, A; Daniels, J; Doust, A; Duncan, C; Hewitt, C; Horne, AW; Jurkovic, D; May, J; Middleton, L; Mol, B; Peace-Gadsby, A; Tong, S | 1 |
| Hastie, R; Italiano, S; Pritchard, N; Readman, E; Tassone, M; Tong, S | 1 |
| Austin-Muttitt, K; Goh, EJH; Lau, AJ; Mullins, JGL; Saburulla, NF; Sivanandam, P; Tan, ARY; Tan, WK; Yap, ZP | 1 |
| Clarke, F; Coomarasamy, A; Daniels, JP; Doust, AM; Duncan, WC; Holland, T; Horne, AW; Jurkovic, D; Middleton, LJ; Moakes, CA; Mol, BW; Nunes, N; Tong, S; Whitaker, LHR | 1 |
4 review(s) available for gefitinib and methotrexate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Methotrexate; Muscle Neoplasms; Neoadjuvant Therapy; Oncogene Proteins v-erbB; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Urinary Bladder Neoplasms; Vinblastine | 2004 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Recent advances in treatment of advanced urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Doxorubicin; Female; Gefitinib; Humans; Immunotherapy; Male; Methotrexate; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quality Improvement; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2012 |
6 trial(s) available for gefitinib and methotrexate
| Article | Year |
|---|---|
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Antineoplastic Agents; Drug Therapy, Combination; Female; Gefitinib; Humans; Injections, Intramuscular; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2013 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Chorionic Gonadotropin; Drug Therapy, Combination; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines; Treatment Outcome | 2018 |
A multi-centre, double-blind, placebo-controlled, randomised trial of combination methotrexate and gefitinib versus methotrexate alone to treat tubal ectopic pregnancies (GEM3): trial protocol.
Topics: Abortifacient Agents, Nonsteroidal; Adolescent; Adult; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Methotrexate; Middle Aged; Multicenter Studies as Topic; Pregnancy; Pregnancy, Tubal; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; United Kingdom; Young Adult | 2018 |
Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.
Topics: Double-Blind Method; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Ectopic; Proportional Hazards Models | 2023 |
21 other study(ies) available for gefitinib and methotrexate
| Article | Year |
|---|---|
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
New thiazole-based derivatives as EGFR/HER2 and DHFR inhibitors: Synthesis, molecular modeling simulations and anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Folic Acid Antagonists; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Structure-Activity Relationship; Thiazoles | 2022 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squamous Cell; Caspase 3; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gefitinib; HL-60 Cells; Humans; Methotrexate; Mitoxantrone; Mouth; Mouth Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Sodium Fluoride; Tumor Cells, Cultured | 2009 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase | 2012 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Medical treatment of ectopic pregnancy: is there something new?
Topics: Abortifacient Agents, Nonsteroidal; Animals; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Methotrexate; Placenta; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2013 |
Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.
Topics: Abortifacient Agents, Nonsteroidal; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Methotrexate; Mice; Mice, SCID; Placenta; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Quinazolines | 2013 |
Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series.
Topics: Abortifacient Agents, Nonsteroidal; Acneiform Eruptions; Adult; Cesarean Section; Chorionic Gonadotropin; Fallopian Tubes; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy Outcome; Pregnancy, Ectopic; Quinazolines; Ultrasonography, Prenatal; Young Adult | 2014 |
Molecular diagnostics and therapeutics for ectopic pregnancy.
Topics: Animals; Biomarkers; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2015 |
Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Death; Cell Line; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Fertility; Gefitinib; Heterografts; Humans; Methotrexate; Mice; Microtubules; Miosis; Placenta; Pregnancy; Pregnancy, Ectopic; Quinazolines; Trophoblasts; Vinblastine; Vinorelbine | 2018 |
Combination methotrexate and gefitinib: A potential medical treatment for inoperable nontubal ectopic pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Drug Therapy, Combination; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Interstitial; Retrospective Studies; Treatment Outcome; Ultrasonography, Prenatal | 2020 |
In Vitro Inhibition of Human Aldehyde Oxidase Activity by Clinically Relevant Concentrations of Gefitinib and Erlotinib: Comparison with Select Metabolites, Molecular Docking Analysis, and Impact on Hepatic Metabolism of Zaleplon and Methotrexate.
Topics: Acetamides; Aldehyde Oxidase; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver; Methotrexate; Molecular Docking Simulation; Protein Conformation; Pyrimidines | 2020 |